✦ LIBER ✦

Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs

✍ Scribed by A.Gardulf Rn; L Hammarström; R Gustafson; T Nyström; C.I.Edvard Smith; R Gustafson; E Jonsson; A Gardulf; E Jonsson; G Möller; G Möller; J Björkander; D Ericson; V Andersen; B So̸eberg; S Fro̸land; M.B Jacobsen

Book ID: 118557390
Publisher: The Lancet
Year: 1995
Tongue: English
Weight: 716 KB
Volume: 345
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(95)90346-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Subcutaneous immunoglobulin replacement

Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies

✍ ElsThM Dams; JosW.M. van der Meer 📂 Article 📅 1995 🏛 The Lancet 🌐 English ⚖ 163 KB

Economic evaluation of immunoglobulin re

Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies

✍ J. Beauté; P. Levy; V. Millet; M. Debré; Y. Dudoit; L. Le Mignot; A. Tajahmady; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 164 KB

Efficacy and safety of home-based subcut

Efficacy and safety of home-based subcutaneous immunoglobulin replacement therapy in paediatric patients with primary immunodeficiencies

✍ M. Borte; E. Bernatowska; H. D. Ochs; C. M. Roifman; the Vivaglobin Study Group 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 253 KB

Rapid subcutaneous immunoglobulin admini

Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies

✍ R. Gustafson; A. Gardulf; S. Hansen; H. Leibl; W. Engl; M. Lindén; A. Müller; L. 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 141 KB

Behavior abnormality following intraveno

Behavior abnormality following intravenous immunoglobulin treatment in patients with primary antibody deficiencies

✍ Sepide Saroukhani; Asghar Aghamohammadi; Javad Mahmoudi-Gharaei; Hassan Abolhass 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB

## Abstract ## Objective Treatment with intravenous immunoglobulin (IVIG) is considered a safe therapy for patients with primary antibody deficiencies (PADs), whilst adverse effects have been frequently reported. Meantime behavioral disorders reactions have not been reported yet. In this study, we

Comparison of the efficacy and safety of

Comparison of the efficacy and safety of immunoglobulin given subcutaneously versus intravenous immunoglobulin in the prevention of infections in patients with primary antibody deficiency syndromes

✍ J. Bjorkander; H. Chapel; G. Spickett 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 203 KB